Paysign

PAYS

Market cap $295M

The average of price targets set by Wall Street analysts indicates a potential upside of 74% in Paysign (PAYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the 17th Annual Southwest IDEAS Investor Conference.

Paysign, Inc. ( PAYS ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Mark Newcomer - Co-Founder, President & CEO Jeffery Baker - CFO & Treasurer Matthew Turner - President of Patient Affordability Conference Call Participants Jacob Stephan - Lake Street Capital Markets, LLC, Research Division Gary Prestopino - Barrington Research Associates, Inc., Research Division Peter Heckmann - D.A. Davidson & Co., Research Division Presentation Operator Good afternoon.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Third Quarter 2025 Financial Results.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Third Quarter 2025 Earnings Call.

Explore the exciting world of Paysign (PAYS -1.42%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

As of Oct. 1, 2025, two stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions.